Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 45 of 469 for:    Inherited Bleeding Disorder

Investigation of the Genetics of Hematologic Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02720679
Recruitment Status : Recruiting
First Posted : March 28, 2016
Last Update Posted : July 12, 2019
Sponsor:
Collaborators:
Boston Children’s Hospital
Baylor College of Medicine
University of Memphis
Information provided by (Responsible Party):
St. Jude Children's Research Hospital

Tracking Information
First Submitted Date March 16, 2016
First Posted Date March 28, 2016
Last Update Posted Date July 12, 2019
Actual Study Start Date June 17, 2016
Estimated Primary Completion Date August 2026   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: March 25, 2016)
Percent of participants who agree to participate [ Time Frame: Day 1, at enrollment ]
It is estimated that approximately 30% of participants (proband) approached for this study will agree to participate and that each proband will have approximately five biologically-related family members who agree to participate.
Original Primary Outcome Measures Same as current
Change History Complete list of historical versions of study NCT02720679 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures
 (submitted: March 25, 2016)
  • Number by type of inherited genetic aberrations associated with hematologic disorders [ Time Frame: Blood drawn at study entry and up to 5 occasions (up to 5 years after enrollment); and/or bone marrow aspirate at study entry and yearly up to 3 occasions (up to 5 years after enrollment) ]
    Germ-line DNA samples from study participants will be extracted and analyzed in order to identify inherited genetic aberrations associated with hematologic disorders. Specific modalities of genomic testing will be case specific. Relevant tests may involve SNP arrays to assess copy number variation, WGS, WES, targeted sequencing of specific candidate genes, RNA-sequencing, X-chromosome inactivation studies, ChIP sequencing and/or other tests. Genetic linkage analyses may be performed using a variety of technologies including high-density SNP arrays, WGS and specific analysis of selected target genes in validation studies.
  • Number by type of modifier genes [ Time Frame: Blood drawn at study entry and up to 5 occasions (up to 5 years after enrollment); and/or bone marrow aspirate at study entry and yearly up to 3 occasions (up to 5 years after enrollment) ]
    Investigators seek to identify modifier genes in individuals in the study population. Methods of analysis will be similar to those for Outcome Measure #2.
  • Number by type of genetic variants [ Time Frame: Blood drawn at study entry and up to 5 occasions (up to 5 years after enrollment); and/or bone marrow aspirate at study entry and yearly up to 3 occasions (up to 5 years after enrollment) ]
    Investigators seek to identify genetic variants associated with treatment outcomes and toxicities in the study population. Methods of analysis will be similar to those for Outcome Measure #2.
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Investigation of the Genetics of Hematologic Diseases
Official Title Investigation of the Genetics of Hematologic Diseases
Brief Summary

The purpose of this study is to collect and store samples and health information for current and future research to learn more about the causes and treatment of blood diseases. This is not a therapeutic or diagnostic protocol for clinical purposes. Blood and bone marrow as well as health information will be used to study and learn about blood diseases by using genetic and/or genomic research. In general, genetic research studies specific genes of an individual; genomic research studies the complete genetic makeup of an individual.

It is not known why many people have blood diseases, because not all genes causing these diseases have been found. It is also not known why some people with the same disease are sicker than others, but this may be related to their genes. By studying the genomes in individuals with blood diseases and their family members, the investigators hope to learn more about how diseases develop and respond to treatment which may provide new and better ways to diagnose and treat blood diseases.

Primary Objective:

  • Establish a repository of DNA and cryopreserved blood cells with linked clinical information from individuals with non-malignant blood diseases and biologically-related family members in order to conduct genomic and functional studies as outlined in the secondary objectives.

Secondary Objectives:

Utilizing the biorepository, investigators aim to:

  • Identify novel mutations that associate with disease status in individuals with unexplained non-malignant blood diseases.
  • Identify modifier genes in individuals with defined monogenic non-malignant blood diseases.
  • Identify genetic variants associated with treatment outcomes and toxicities for individuals with non-malignant blood disease.
  • Use transcriptomics, proteomics and metabolomics to investigate biomarkers for sickle cell disease (SCD) progression, paint events and the long-term cellular and molecular effects of hydroxyurea therapy.
Detailed Description

Participants will be individuals (proband) receiving therapy or expert consultation regarding a non-malignant hematologic disorder. We propose to use genomics, trancriptomics, proteomics and metabolomic analysis coupled with family linkage studies to identify causal mutations in individuals with undefined hematologic disorders and to characterize genetic modifiers of defined monogenic blood diseases.

A detailed medical history will be obtained, including demographic information for each proband. For each identified biologically-related family member, a medical history questionnaire will be obtained. The family history and pedigree will be reviewed in conjunction with a geneticist/genetic counselor. The implications of genetic testing will be explained. If participants consent for future contact, this will take place annually for updates on medical and family history.

All probands will provide peripheral blood samples, and probands who are undergoing a bone marrow aspirate/biopsy for clinical purposes will provide additional aspirates. Biological family members will provide peripheral blood samples as a source for DNA.

Study Type Observational [Patient Registry]
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration 10 Years
Biospecimen Retention:   Samples With DNA
Description:
Blood samples and bone marrow aspirate samples.
Sampling Method Non-Probability Sample
Study Population Participants will be (1) individuals with a non-malignant hematologic disorder confirmed or suspected to have a genetic basis, and (2) affected and unaffected family members of those individuals who are willing to provide clinical data and undergo genetic testing.
Condition
  • Bone Marrow Failure Syndromes
  • Erythrocyte Disorder
  • Leukocyte Disorder
  • Hemostasis
  • Blood Coagulation Disorder
  • Sickle Cell Disease
  • Dyskeratosis Congenita
  • Diamond-Blackfan Anemia
  • Congenital Thrombocytopenia
  • Severe Congenital Neutropenia
  • Fanconi Anemia
Intervention Not Provided
Study Groups/Cohorts Study Participants
Participants will be (1) individuals with a non-malignant hematologic disorder confirmed or suspected to have a genetic basis, and (2) affected and unaffected family members of those individuals who are willing to provide clinical data and undergo genetic testing.
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: March 25, 2016)
1716
Original Estimated Enrollment Same as current
Estimated Study Completion Date August 2026
Estimated Primary Completion Date August 2026   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • An individual (proband) receiving therapy or expert consultation regarding a non-malignant hematologic disorder.
  • A biologically-related individual to the identified proband to include: first, second or third degree relatives.

Exclusion Criteria:

  • None
Sex/Gender
Sexes Eligible for Study: All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers No
Contacts
Contact: Marcin Wlodarski, MD 866-278-5833 referralinfo@stjude.org
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT02720679
Other Study ID Numbers INSIGHT-HD
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement Not Provided
Responsible Party St. Jude Children's Research Hospital
Study Sponsor St. Jude Children's Research Hospital
Collaborators
  • Boston Children’s Hospital
  • Baylor College of Medicine
  • University of Memphis
Investigators
Principal Investigator: Marcin Wlodarski, MD St. Jude Children's Research Hospital
PRS Account St. Jude Children's Research Hospital
Verification Date July 2019